Australian guinea pigs step up for virus trial

Original article by Natasha Robinson
The Australian Financial Review – Page: 1 & 5 : 20-May-20

Australia-based Q-Pharm will shortly commence a phase one clinical trial of a coronavirus vaccine that is being developed by US biopharmaceutical group Novavax. Some 131 people in Melbourne and Brisbane have volunteered to participate in the clinical trial. Q-Pharm will also undertake phase 1 clinical trials of a potential vaccine that being developed by the University of Queensland. Meanwhile, the Walter & Eliza Hall Institute of Medical Research will commence a clinical trial of antimalarial drug hydroxychloroquine.

CORPORATES
Q-PHARM PTY LTD, UNIVERSITY OF QUEENSLAND, WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH

Mesoblast falls 42pc as investors lose heart

Original article by Jessica Gardner, James Thomson
The Australian Financial Review – Page: 13 & 18 : 15-Jun-16

The market capitalisation of Australian biotechnology group Mesoblast has fallen to $A750m following a 42.2 per cent fall in its share price on 14 June 2016. The stock closed at a seven-year low of $A1.11 after Teva Pharmaceutical Industries advised that it will not finance the final round of clinical trials for Mesoblast’s stem-cell treatment for heart failure. Mesoblast had cash reserves of around $US100m at the end of the March quarter, and CEO Silviu Itescu is confident that the group can secure funding partners before its cash reserves are exhausted.

CORPORATES
MESOBLAST LIMITED – ASX MSB, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, CEPHALON INCORPORATED, CANACCORD GENUITY (AUSTRALIA) LIMITED

Diabetes trial success

Original article by Tim Binsted
The Australian Financial Review – Page: 22 : 9-Jun-15

Listed biotechnology group Mesoblast has reported encouraging results from the phase two trial of a treatment for diabetic nephropathy. CEO Silviu Itescu says nearly two million people had the diabetes-related kidney disease in 2013. The clinical trial found that the stem cell-based treatment showed that participants had improved kidney function and experienced no adverse side-effects.

CORPORATES
MESOBLAST LIMITED – ASX MSB, AMERICAN DIABETES ASSOCIATION, CELGENE INCORPORATED, SIRTEX MEDICAL LIMITED – ASX SRX

ResMed falls 18pc as trial boosts patients’ risk of dying

Original article by Jessica Gardner
The Australian Financial Review – Page: 15 & 20 : 15-May-15

Wilson HTM has changed its recommendation on ResMed from "buy" to "sell" after clinical trials of a sleep apnoea device showed that patients with a heart condition were at greater risk of death when using it. The results of the clinical trial prompted ResMed’s Australian-listed shares to close $A1.52 lower at $A6.73 on 14 May 2015. ResMed notes that the ventilation machine used in the clinical trial accounted for just seven per cent of its revenue in the last financial year.

CORPORATES
RESMED INCORPORATED – ASX RMD, WILSON HTM INVESTMENT GROUP LIMITED – ASX WIG, CREDIT SUISSE (AUSTRALIA) LIMITED, DEUTSCHE BANK AG, UBS HOLDINGS PTY LTD

Sirtex sheds $1b after cancer therapy trial disappoints

Original article by Jessica Gardner
The Australian Financial Review – Page: 11 & 17 : 18-Mar-15

Sirtex Medical’s shares closed 55 per cent lower at $A17.53 on 17 March 2015, after the group released the results of a seven-year clinical trial of its SIR-Spheres treatment for liver cancer. The trial found that the treatment does not offer much improvement compared with traditional treatments such as chemotherapy. However, Sirtex intends to make more extensive data on the clinical trial available in May

CORPORATES
SIRTEX MEDICAL LIMITED – ASX SRX, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, MESOBLAST LIMITED – ASX MSB, CSL LIMITED – ASX CSL, ONCOSIL MEDICAL LIMITED – ASX OSL, MORGANS FINANCIAL LIMITED, BLOOMFIELD COLLIERIES, UBS HOLDINGS PTY LTD, WILSON HTM INVESTMENT GROUP LIMITED – ASX WIG, AUSTRALIAN ETHICAL INVESTMENT LIMITED – ASX AEF

Stem cell trial set for children with cerebral palsy

Original article by Kate Hagan
The Age – Page: 8 : 24-Nov-14

Iona Novak, head of research at the Cerebral Palsy Alliance in Australia, has announced a new clinical trial of a therapy using umbilical cord blood infusions. About 20 children aged up to 10 years will take part in the study to be co-ordinated by the Murdoch Children’s Research Institute. Meanwhile the Royal Australasian College of Physicians is urging parents of children with cerebral palsy against unproven stem cell treatments offered in countries such as Panama, China, India and Russia

CORPORATES
CEREBRAL PALSY ALLIANCE, MURDOCH CHILDREN’S RESEARCH INSTITUTE, THE ROYAL AUSTRALASIAN COLLEGE OF PHYSICIANS

Skin cancer drug developer plans to list

Original article by Sally Rose
The Australian Financial Review – Page: 19 : 29-Sep-14

Melbourne-based Ascend Biopharmaceuticals will offer its shares at $A0.35 in an IPO that aims to raise between $A9m and $A11m. Proceeds of the float will be used to finance clinical trials of drugs that are intended to treat skin cancer and breast cancer. Ascend shares are slated to list on the Australian sharemarket on 14 November 2014

CORPORATES
ASCEND BIOPHARMACEUTICALS LIMITED, ONYVAX, ALCHEMIA LIMITED – ASX ACL, AMRAD CORP LIMITED, F HOFFMAN-LA ROCHE LIMITED, F HOFFMAN-LA ROCHE AG, IMMATICS, LODGE CORPORATE PTY LTD, TRANSGENE

Breathing technique to help avoid radiation

Original article by Kate Hagan
The Age – Page: 2 : 9-Jul-14

Breast cancer patients receiving radiation treatment have an elevated risk of developing heart problems, of up to 2%, if the tumour is on the left. However, Epworth Hospital in Melbourne has had good results with teaching the women breathing techniques, so that they can stay still while the radiation doses are administered. Oncologist Andrew See says a clinical trial with a control group will be conducted to show whether the approach is worth pursuing

CORPORATES
EPWORTH HOSPITAL